TRDA Q1 2025 Earnings — Entrada Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TRDAEntrada Therapeutics, Inc.

$502M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M-65.2% YoY

Gross Profit

$21M100.0% margin

Operating Income

-$22M-106.0% margin

Net Income

-$17M-84.4% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

-45.0%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$40M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$486M

Total Liabilities

$69M

Stockholders' Equity

$417M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$59M	-65.2%
Gross Profit	$21M	$59M	-65.2%
Operating Income	-$22M	$21M	-203.2%
Net Income	-$17M	$23M	-173.8%

Revenue Segments

License

$2M100%